Market & Regulation
Novo Nordisk and AWS partner on AI for drug discovery
AI Newshigh confidence
Why it matters
- →The partnership aims to accelerate drug discovery timelines using AI.
- →It integrates computational and laboratory research, potentially increasing efficiency.
- →The collaboration could lead to faster development of treatments for chronic diseases.
Novo Nordisk has partnered with AWS to enhance its drug discovery efforts using AI. The collaboration will utilize AWS's cloud services and AI tools to streamline research workflows and reduce development timelines. A new co-innovation hub in London will facilitate direct collaboration between AWS engineers and Novo Nordisk scientists. This partnership aims to integrate AI more deeply into the drug development process, potentially accelerating the creation of new therapies for chronic diseases.
Read originalThe story around this
Earlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
More in Market & Regulation
© TechCrunch AIMarket & Regulationother
Judge allows NAACP lawsuit over xAI pollution to proceed
xAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
TechCrunch AI
© TechCrunch AI